Sierra Oncology, Inc. (SRRA)

NASDAQ: SRRA · IEX Real-Time Price · USD
54.78
0.05 (0.09%)
At close: May 27, 2022 4:00 PM
54.75
-0.03 (-0.05%)
After-hours:May 27, 2022 4:25 PM EDT
Market Cap1.34B
Revenue (ttm)n/a
Net Income (ttm)-102.67M
Shares Out24.42M
EPS (ttm)-6.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume152,446
Open54.78
Previous Close54.73
Day's Range54.74 - 54.79
52-Week Range14.91 - 54.97
Beta0.01
AnalystsBuy
Price Target56.10 (+2.4%)
Earnings DateMay 6, 2022

About SRRA

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreem...

IndustryBiotechnology
IPO DateJul 16, 2015
CEOStephen Dilly
Employees109
Stock ExchangeNASDAQ
Ticker SymbolSRRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for SRRA stock is "Buy." The 12-month stock price forecast is 56.1, which is an increase of 2.41% from the latest price.

Price Target
$56.1
(2.41% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting

SAN MATEO, Calif.--(BUSINESS WIRE)---- $SRRA #ASCO22--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, toda...

1 day ago - Business Wire

Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association An...

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two ab...

2 weeks ago - Business Wire

Sierra Oncology Reports First Quarter 2022 Results

SAN MATEO, Calif--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today report...

3 weeks ago - Business Wire

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twe...

3 weeks ago - Business Wire

SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sierra Oncology, I...

Other symbols:GSK
3 weeks ago - Business Wire

SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NasdaqGM: SRRA) to GlaxoSmithKline plc (NYSE: GSK). Under the terms of the proposed trans...

Other symbols:GSK
3 weeks ago - Business Wire

RayzeBio Appoints Angie You, Ph.D., to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of di...

1 month ago - Business Wire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sierra Oncology, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Sierra Oncology, Inc. ("Sierra") (NASDAQ: SRRA) regarding possible breaches of fiduciary duties and other v...

1 month ago - Newsfile Corp

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SRRA, ATRS, OBNK

NEW YORK , April 13, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols:OBNK
1 month ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.

NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "...

Other symbols:GSK
1 month ago - PRNewsWire

Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK

Sierra Oncology (NASDAQ: SRRA) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC (LON: GSK) for $55 a share in cash. That represents a total equity value of $1.9...

Other symbols:GSK
1 month ago - Invezz

Why Is Sierra Oncology (SRRA) Stock Up Today?

Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.

1 month ago - InvestorPlace

Sierra Oncology Stock Is Soaring: Here's Why

Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, represe...

1 month ago - Benzinga

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

Shares of Sierra Oncology Inc. SRRA, +3.10% soared 37.3% in premarket trading on Wednesday after GlaxoSmithKline GSK, +0.11% GSK, +0.63% said it would buy the company for $1.9 billion. Sierra is develop...

Other symbols:GSK
1 month ago - Market Watch

Why Sierra Oncology Stock Is Soaring Today

GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.

1 month ago - The Motley Fool

GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal

GlaxoSmithKline plc (NYSE: GSK) has agreed to acquire Sierra Oncology Inc (NASDAQ: SRRA) for $55 per share in cash, representing an approximate total equity value of $1.9 billion (£1.5 billion). Sierra'...

Other symbols:GSK
1 month ago - Benzinga

SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Sierra Oncology, Inc. (NASDAQ: SRRA) to GlaxoSmithKline plc for $55.00 per share in cash is...

1 month ago - Business Wire

GlaxoSmithKline to buy Sierra Oncology for $1.9 billion.

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

Other symbols:GSK
1 month ago - Market Watch

GSK to buy Sierra Oncology for $1.9 billion

Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday.

Other symbols:GSK
1 month ago - Reuters

GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra...

Other symbols:GSK
1 month ago - Business Wire

Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company ...

2 months ago - Business Wire

Sierra Oncology Reports 2021 Year End Results

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today reported its financial...

2 months ago - Business Wire

Sierra Oncology Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that the und...

3 months ago - Business Wire

Sierra Oncology to Participate in Guggenheim Oncology Conference

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the company ...

3 months ago - Business Wire

Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities

SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the closing ...

3 months ago - Business Wire